This TAP compound is wholly owned by ImmunoGen and is in clinical testing for the treatment of multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and ovarian cancer. IMGN901 has been granted orphan drug designation for the first three of these cancers in the US and in Europe. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents, and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are currently six TAP compounds in the clinic, with a wealth of clinical data reported with the technology.